Drug intelligence / Profile preview

CBIO-007

Development stage: Preclinical
Lead developer: Chimera Bioengineering
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**CBIO-007** is a conditionally armed chimeric antigen receptor (CAR)-T cell therapy in preclinical development for solid tumors, including colorectal cancer and triple-negative breast cancer. It employs Chimera Bioengineering's GOLD platform, which reprograms RNA gene regulation circuits to enable controllable activation of CAR-T cells specifically in the tumor microenvironment, enhancing safety and efficacy against solid tumors.[1][12][14]

Targets

CD7 (CD7 antigen)

Beyond the preview

Go deeper on CBIO-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBIO-007.

Explore the full profile